Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Purpose. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas. Combining Hsp90 inhibitors to enhance endoplasmic reticulum stress with mTOR inhibition results in dramatic MPNST shrinkage in a genetically engineered MPNST mouse model. Ganetespib is an injectable poten...

Full description

Bibliographic Details
Main Authors: AeRang Kim, Yao Lu, Scott H. Okuno, Denise Reinke, Ophélia Maertens, John Perentesis, Mitali Basu, Pamela L. Wolters, Thomas De Raedt, Sant Chawla, Rashmi Chugh, Brian A. Van Tine, Geraldine O’Sullivan, Alice Chen, Karen Cichowski, Brigitte C. Widemann
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Sarcoma
Online Access:http://dx.doi.org/10.1155/2020/5784876

Internet

http://dx.doi.org/10.1155/2020/5784876

Similar Items